MDGL
Price
$514.23
Change
-$14.71 (-2.78%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
12.01B
111 days until earnings call
Intraday BUY SELL Signals
NAGE
Price
$6.99
Change
-$0.19 (-2.65%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
573.01M
118 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MDGL vs NAGE

Header iconMDGL vs NAGE Comparison
Open Charts MDGL vs NAGEBanner chart's image
Madrigal Pharmaceuticals
Price$514.23
Change-$14.71 (-2.78%)
Volume$3.3K
Capitalization12.01B
Niagen Bioscience
Price$6.99
Change-$0.19 (-2.65%)
Volume$18.35K
Capitalization573.01M
MDGL vs NAGE Comparison Chart in %
View a ticker or compare two or three
VS
MDGL vs. NAGE commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and NAGE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (MDGL: $528.94 vs. NAGE: $7.18)
Brand notoriety: MDGL and NAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 129% vs. NAGE: 46%
Market capitalization -- MDGL: $11.69B vs. NAGE: $557.84M
MDGL [@Biotechnology] is valued at $11.69B. NAGE’s [@Biotechnology] market capitalization is $557.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileNAGE’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • NAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than NAGE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 5 TA indicator(s) are bullish while NAGE’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 5 bullish, 5 bearish.
  • NAGE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NAGE is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +11.15% price change this week, while NAGE (@Biotechnology) price change was +4.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

MDGL is expected to report earnings on Mar 04, 2026.

NAGE is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($12B) has a higher market cap than NAGE($573M). MDGL YTD gains are higher at: 71.417 vs. NAGE (35.344). NAGE has higher annual earnings (EBITDA): 18.1M vs. MDGL (-266.74M). MDGL has more cash in the bank: 797M vs. NAGE (60.3M). NAGE has less debt than MDGL: NAGE (3.29M) vs MDGL (124M). MDGL has higher revenues than NAGE: MDGL (516M) vs NAGE (116M).
MDGLNAGEMDGL / NAGE
Capitalization12B573M2,094%
EBITDA-266.74M18.1M-1,474%
Gain YTD71.41735.344202%
P/E RatioN/A29.92-
Revenue516M116M445%
Total Cash797M60.3M1,322%
Total Debt124M3.29M3,767%
FUNDAMENTALS RATINGS
MDGL vs NAGE: Fundamental Ratings
MDGL
NAGE
OUTLOOK RATING
1..100
1663
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
2088
SMR RATING
1..100
9625
PRICE GROWTH RATING
1..100
3764
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
1385

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (64) in the Pharmaceuticals Other industry is in the same range as NAGE (77) in the Chemicals Specialty industry. This means that MDGL’s stock grew similarly to NAGE’s over the last 12 months.

MDGL's Profit vs Risk Rating (20) in the Pharmaceuticals Other industry is significantly better than the same rating for NAGE (88) in the Chemicals Specialty industry. This means that MDGL’s stock grew significantly faster than NAGE’s over the last 12 months.

NAGE's SMR Rating (25) in the Chemicals Specialty industry is significantly better than the same rating for MDGL (96) in the Pharmaceuticals Other industry. This means that NAGE’s stock grew significantly faster than MDGL’s over the last 12 months.

MDGL's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as NAGE (64) in the Chemicals Specialty industry. This means that MDGL’s stock grew similarly to NAGE’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as NAGE (100) in the Chemicals Specialty industry. This means that MDGL’s stock grew similarly to NAGE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLNAGE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 23 days ago
80%
Bearish Trend 8 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signal:
Gain/Loss:
NAGE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UPSX8.740.30
+3.55%
Tradr 2X Long UPST Daily ETF
FLEU33.050.29
+0.90%
Franklin FTSE Eurozone ETF
EVV10.140.03
+0.30%
Eaton Vance Limited
FEBM30.09N/A
-0.01%
FT Vest U.S. Eq Max Buffr ETF - Feb
IGHG78.21-0.40
-0.51%
ProShares Investment Grade—Intr Rt Hdgd

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-2.32%
ALXO - MDGL
56%
Loosely correlated
-2.29%
IPHA - MDGL
44%
Loosely correlated
-10.28%
RNAC - MDGL
43%
Loosely correlated
+3.84%
GHRS - MDGL
43%
Loosely correlated
+5.49%
LCTX - MDGL
43%
Loosely correlated
+6.04%
More

NAGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAGE has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NAGE jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAGE
1D Price
Change %
NAGE100%
+0.28%
AXON - NAGE
43%
Loosely correlated
-0.47%
MDGL - NAGE
41%
Loosely correlated
-2.32%
AMRN - NAGE
35%
Loosely correlated
+0.75%
CYTK - NAGE
35%
Loosely correlated
-0.84%
ARRY - NAGE
34%
Loosely correlated
-8.69%
More